-
Product Insights
Anorexia Nervosa – Drugs In Development, 2023
Global Markets Direct’s, ‘Anorexia Nervosa - Drugs In Development, 2023’, provides an overview of the Anorexia Nervosa pipeline landscape. The report provides comprehensive information on the therapeutics under development for Anorexia Nervosa, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Chemotherapy Induced Nausea and Vomiting – Drugs In Development, 2023
Global Markets Direct’s, ‘Chemotherapy Induced Nausea and Vomiting - Drugs In Development, 2023’, provides an overview of the Chemotherapy Induced Nausea and Vomiting pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Nausea and Vomiting, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Erectile Dysfunction – Drugs In Development, 2023
Global Markets Direct’s, ‘Erectile Dysfunction - Drugs In Development, 2023’, provides an overview of the Erectile Dysfunction pipeline landscape. The report provides comprehensive information on the therapeutics under development for Erectile Dysfunction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Appetite (Eating) Disorders – Drugs In Development, 2023
Global Markets Direct’s, ‘Appetite (Eating) Disorders - Drugs In Development, 2023’, provides an overview of the Appetite (Eating) Disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development for Appetite (Eating) Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Mild Cognitive Impairment – Drugs In Development, 2023
Global Markets Direct’s, ‘Mild Cognitive Impairment - Drugs In Development, 2023’, provides an overview of the Mild Cognitive Impairment pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mild Cognitive Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Cognitive Impairment – Drugs In Development, 2023
Global Markets Direct’s, ‘Cognitive Impairment - Drugs In Development, 2023’, provides an overview of the Cognitive Impairment pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cognitive Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Tadalafil in Erectile Dysfunction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tadalafil in Erectile Dysfunction report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tadalafil in Erectile Dysfunction Drug Details: Tadalafil (INT-0007) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tadalafil in Erectile Dysfunction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tadalafil in Erectile Dysfunction report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Tadalafil in Erectile DysfunctionDrug Details:Tadalafil (INT-0007) is under development for the treatment of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Montelukast Sodium in Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Montelukast Sodium in Alzheimer's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Montelukast Sodium in Alzheimer's DiseaseDrug Details:Montelukast sodium (INT-0043) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Azenosertib in Fallopian Tube Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Azenosertib in Fallopian Tube Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Azenosertib in Fallopian Tube CancerDrug Details:Azenosertib (ZNC-3) is under development for the...